LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Al-Rawhani, Mohammed A.; Cheah, Boon Chong; MacDonald, Alasdair Iain; Martin, Christopher; Hu, Chunxiao; Beeley, James; Gouveia, Luiz Carlos; Grant, James P.; Campbell, Gordon; Barrett, Michael P.; Cumming, David R.S. (2017)
Publisher: IEEE
Languages: English
Types: Article
Subjects:
Elevated cholesterol levels are associated with a greater risk of developing cardiovascular disease and other illnesses, making it a prime candidate for detection on a disposable biosensor for rapid point of care diagnostics. One of the methods to quantify cholesterol levels in human blood serum uses an optically mediated enzyme assay and a bench top spectrophotometer. The bulkiness and power hungry nature of the equipment limits its usage to laboratories. Here, we present a new disposable sensing platform that is based on a complementary metal oxide semiconductor process for total cholesterol quantification in pure blood serum. The platform that we implemented comprises readily mass-manufacturable components that exploit colorimetric changes of cholesterol oxidase and cholesterol esterase reactions. We have shown that our quantification results are comparable to that obtained by a bench top spectrophotometer. Using the implemented device, we have measured cholesterol concentration in human blood serum as low as 29 μM with a limit of detection at 13 μM, which is approximately 400 times lower than average physiological range, implying that our device also has the potential to be used for applications that require greater sensitivity.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] P. Yager, G. J. Domingo, and J. Gerdes, “Point-of-care diagnostics for global health,” Annu. Rev. Biomed. Eng., vol. 10, pp. 107-144, Jan. 2008.
    • [2] I. V. Jani and T. F. Peter, “How point-of-care testing could drive innovation in global health,” New England J. Med., vol. 368, no. 24, pp. 2319-2324, Jun. 2013.
    • [3] D. A. Giljohann and C. A. Mirkin, “Drivers of biodiagnostic development,” Nature, vol. 462, pp. 461-464, Nov. 2009.
    • [4] A. P. F. Turner, “Biosensors: Sense and sensibility,” Chem. Soc. Rev., vol. 42, no. 8, pp. 3184-3196, Apr. 2013.
    • [5] C. D. Chin et al., “Microfluidics-based diagnostics of infectious diseases in the developing world,” Nature Med., vol. 17, no. 8, pp. 1015-1019, Aug. 2011.
    • [6] X. Zhang, H. Ju, and J. Wang, Electrochemical Sensors, Biosensors and Their Biomedical Applications. San Diego, CA, USA: Academic, 2008, pp. 57-67.
    • [7] M. S. Monteiro, M. Carvalho, M. L. Bastos, and P. G. De Pinho, “Metabolomics analysis for biomarker discovery: Advances and challenges,” Current Med. Chem., vol. 20, no. 2, pp. 257-271, Jan. 2013.
    • [8] A. Nordström and R. Lewensohn, “Metabolomics: Moving to the clinic,” J. Neuroimmune Pharmacol., vol. 5, no. 1, pp. 4-17, Mar. 2010.
    • [9] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults findings from the third national health and nutrition examination survey,” J. Amer. Med. Assoc., vol. 287, no. 3, pp. 356-359, 2002.
    • [10] Scandinavian Simvastatin Survival Study Group, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S),” Lancet, vol. 344, no. 8934, pp. 1383-1389, Nov. 1994.
    • [11] J. R. Hupp, “Lowering blood cholesterol to prevent heart disease,” J. Oral Maxillofac. Surgery, vol. 43, no. 9, p. 741, Sep. 1985.
    • [12] M. L. Stefanick, S. Mackey, M. Sheehan, N. Ellsworth, W. L. Haskell, and P. D. Wood, “Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol,” New England J. Med., vol. 339, no. 1, pp. 12-20, 1998.
    • [13] M. J. Martin, W. S. Browner, S. B. Hulley, L. H. Kuller, and D. Wentworth, “Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361 662 men,” Lancet, vol. 328, no. 8513, pp. 933-936, 1986.
    • [14] D. Mozaffarian et al., “Heart disease and stroke statistics-2015 update,” Circulation, vol. 131, no. 4, pp. e29-e322 , Jan. 2015.
    • [15] A Global Brief on Hypertension-Silent Killer, Global Public Health Crisis, Switzerland: World Health Organization, 2013.
    • [16] E.-H. Yoo and S.-Y. Lee, “Glucose biosensors: An overview of use in clinical practice.,” Sensors, vol. 10, no. 5, pp. 4558-4576, Jan. 2010.
    • [17] L. Sommer, Analytical Absorption Spectrophotometry in the Visible and Ultraviolet. New York, NY, USA: Elsevier, 1989.
    • [18] J. Monk, “Developments in microelectronics technology and the economics of the semiconductor industry,” Int. J. Soc. Econ., vol. 7, no. 1, pp. 13-23, 1980.
    • [19] D. Lombardo and O. Guy, “A rapid and convenient colorimetric assay for cholesterol ester hydrolase activity,” Biochimie, vol. 61, no. 3, pp. 415-417, Jun. 1979.
    • [20] Y. Kayamori, H. Hatsuyama, T. Tsujioka, M. Nasu, and Y. Katayama, “Endpoint colorimetric method for assaying total cholesterol in serum with cholesterol dehydrogenase,” Clin. Chem., vol. 45, no. 12, pp. 2158-2163, Dec. 1999.
    • [21] S. Singh, P. R. Solanki, M. K. Pandey, and B. D. Malhotra, “Cholesterol biosensor based on cholesterol esterase, cholesterol oxidase and peroxidase immobilized onto conducting polyaniline films,” Sens. Actuators B Chem., vol. 115, no. 1, pp. 534-541, May 2006.
    • [22] W. Richmond, “Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to enzymatic assay of total cholesterol in serum,” Clin. Chem., vol. 19, no. 12, pp. 1350-1356, 1973.
    • [23] P. Srisawasdi, N. Prasertsincharoen, and M. H. Kroll, “Porcine pancreas: A superior source of cholesterol esterase for total serum cholesterol assay by the enzymatic kinetic method,” J. Clin. Lab. Anal., vol. 26, no. 6, pp. 420-430, Nov. 2012.
    • [24] C. C. Allain, L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu, “Enzymatic determination of total serum cholesterol,” Clin. Chem., vol. 20, no. 4, pp. 470-574, Apr. 1974.
    • [25] J. R. Harris, Cholesterol Binding and Cholesterol Transport Proteins. New York, NY, USA: Springer, 2010.
    • [26] E. R. Fossum, “CMOS image sensors: Electronic camera-on-a-chip,” IEEE Trans. Electron Devices, vol. 44, no. 10, pp. 1689-1698, Oct. 1997.
    • [27] B. C. Cheah et al., “An integrated circuit for chip-based analysis of enzyme kinetics and metabolite quantification,” IEEE Trans. Biomed. Circuits Syst., vol. 10, no. 3, pp. 721-730, Jun. 2016.
    • [28] S. D. Goodman et al., “Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults,” Arch. Int. Med., vol. 148, no. 1, pp. 36-69, 1988. Michael P. Barrett is currently a Professor of Biochemical Parasitology with the University of Glasgow, Glasgow, U.K., and directs the Glasgow Polyomics and the Scottish Metabolomics Facilities. He is also the Deputy Director of the Scottish Universities Life Sciences Alliance and also an Associate Director of the U.S.-based Consortium of Parasitic Drug Development. He chaired the Kinetoplastids drug efficacy working group at the World Health Organization. He has pioneered application of novel technologies to diagnostics and new antimicrobial interventions and the use of microfluidics for separation of parasites from mammalian body fluids. David R. S. Cumming (M'97-SM'08-F'13) received the B.Eng. degree in electronic and electrical engineering from the University of Glasgow, Glasgow, U.K., in 1989, and the Ph.D. degree from the Cambridge University, Cambridge, U.K., in 1993. He currently leads the Microsystem Technology Group, School of Engineering, University of Glasgow, where he is also the Co-Founder of its spin-out, Mode Diagnostics. His research on CMOS ion sensitive array technology has also been commercialized into the ion torrent next-generation sequencing system. He was a recipient of the Royal Society Wolfson Merit Award.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Funded by projects

Cite this article